All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

bepotastine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
antihistaminics	341	125602-71-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: bepotastine bepotastine besilate bepreve bepotastine besylate	Molecular weight: 388.89 Formula: C21H25ClN2O3 CLOGP: 0.28 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 62.66 ALOGS: -3.89 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	85 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,SIK2,TEK,TGFBR1	26
kinase-selectivity-class	AXL,EIF2AK3,GRK2,SIK2,STK33,TEK	6
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Sept. 8, 2009	FDA	BAUSCH AND LOMB INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Interstitial lung disease	26.92	25.35	15	1153	76390	90550889

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatic function abnormal	38.55	26.57	21	1073	51546	42568695
Interstitial lung disease	35.23	26.57	23	1071	78439	42541802
Nasal turbinate abnormality	27.59	26.57	4	1090	54	42620187

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Interstitial lung disease	58.36	22.35	37	2403	139297	110447562
Hepatic function abnormal	56.58	22.35	31	2409	89264	110497595
Pemphigoid	35.08	22.35	14	2426	19693	110567166
Erythema multiforme	34.16	22.35	14	2426	21083	110565776
Neutrophil count decreased	33.71	22.35	25	2415	120916	110465943
Platelet count decreased	32.10	22.35	32	2408	230411	110356448
Drug eruption	29.53	22.35	17	2423	53642	110533217
Nasal turbinate abnormality	29.21	22.35	4	2436	41	110586818
Hypopituitarism	23.07	22.35	7	2433	4383	110582476

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D018926	Anti-Allergic Agents
FDA EPC	N0000175587	Histamine-1 Receptor Antagonist
CHEBI has role	CHEBI:37955	H<small><sub>1</sub></small>-receptor antagonist
CHEBI has role	CHEBI:50857	anti-allergic agent
CHEBI has role	CHEBI:66981	ophthalmology drug
CHEBI has role	CHEBI:50177	dermatologic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Allergic conjunctivitis	indication	473460002	DOID:11204

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.54	acidic
pKa2	9.51	Basic
pKa3	4.25	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST				DRUGBANK	CHEMBL

External reference:

ID	Source
4029223	VUID
N0000181653	NUI
D01654	KEGG_DRUG
658552	RXNORM
C2698371	UMLSCUI
CHEBI:71204	CHEBI
CHEMBL1201758	ChEMBL_ID
DB04890	DRUGBANK_ID
CHEMBL1201759	ChEMBL_ID
C108476	MESH_SUPPLEMENTAL_RECORD_UI
164522	PUBCHEM_CID
7466	IUPHAR_LIGAND_ID
C511534	MESH_SUPPLEMENTAL_RECORD_UI
7648	INN_ID
190786-44-8	SECONDARY_CAS_RN
HYD2U48IAS	UNII
167734	MMSL
26713	MMSL
347164	MMSL
4029223	VANDF
4029224	VANDF
010865	NDDF
010866	NDDF
443616002	SNOMEDCT_US
707083009	SNOMEDCT_US
770926005	SNOMEDCT_US
HYD2U48IAS	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Bepotastine Besilate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-7055	SOLUTION/ DROPS	15 mg	OPHTHALMIC	ANDA	24 sections
Bepotastine Besilate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-7055	SOLUTION/ DROPS	15 mg	OPHTHALMIC	ANDA	24 sections
Bepreve	HUMAN PRESCRIPTION DRUG LABEL	1	24208-629	SOLUTION/ DROPS	15 mg	OPHTHALMIC	NDA	21 sections
Bepotastine Besilate	HUMAN PRESCRIPTION DRUG LABEL	1	24208-630	SOLUTION/ DROPS	15 mg	OPHTHALMIC	NDA authorized generic	22 sections
Bepotastine Besilate Ophthalmic Solution 1.5%	Human Prescription Drug Label	1	46708-598	SOLUTION/ DROPS	15 mg	OPHTHALMIC	ANDA	21 sections
BEPREVE	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6299	SOLUTION/ DROPS	15 mg	OPHTHALMIC	NDA	21 sections
Bepotastine Besilate Ophthalmic Solution 1.5%	Human Prescription Drug Label	1	62332-598	SOLUTION/ DROPS	15 mg	OPHTHALMIC	ANDA	21 sections
Bepotastine Besilate	HUMAN PRESCRIPTION DRUG LABEL	1	70069-711	SOLUTION	15 mg	OPHTHALMIC	ANDA	21 sections
Bepotastine Besilate	HUMAN PRESCRIPTION DRUG LABEL	1	70069-712	SOLUTION	15 mg	OPHTHALMIC	ANDA	21 sections
Bepotastine Besilate	HUMAN PRESCRIPTION DRUG LABEL	1	82260-630	SOLUTION/ DROPS	15 mg	OPHTHALMIC	NDA authorized generic	21 sections